ReShape Lifesciences Appoints Seasoned Gross sales and Advertising and marketing Govt, Nick Ansari, as Senior Vice President of World Industrial Operations

0
3
Advertisement

ReShape Lifesciences Inc

SAN CLEMENTE, Calif., Aug. 23, 2022 (GLOBE NEWSWIRE) — ReShape Lifesciences™ (Nasdaq: RSLS), the premier physician-led weight reduction and metabolic well being options firm, at this time introduced that the corporate has appointed Nick Ansari as Senior Vice President of World Industrial Operations, efficient September 6, 2022. Mr. Ansari, who, from 2014 to 2019 was Senior Vice President World Gross sales for Enteromedics, the predecessor firm to Reshape, will likely be chargeable for strengthening the executional efficiencies of the gross sales and advertising and marketing staff, worldwide. On this position, he’ll report on to Mr. Paul F. Hickey, ReShape’s President and Chief Govt Officer.

“Nick is a confirmed government who, throughout his 30 12 months profession, has constructed a observe report of efficiently creating and executing gross sales initiatives that drive industrial income and strengthen market share for rising and international medical machine firms. This contains his previous successes, not solely at Enteromedics, but additionally at Johnson & Johnson, Medtronic and Stryker Company, amongst others,” said Mr. Hickey. “Given his depth of relationships, the popularity he has achieved and the information he possesses from his prior expertise with Enteromedics, we’re assured that Nick’s management will positively impression continued international gross sales development of the Lap-Band®. Nick will play a important position on the ReShape staff as we execute on our objective of turning into the worldwide chief in physician-led weight reduction and metabolic well being options, with a complete, built-in slate of services and products.”

“The reversible, anatomy-sparing Lap-Band®, which has been implanted in multiple million sufferers, globally, during the last 20 years, has confirmed itself to be a secure and efficient strategy for weight reduction and I look ahead to bringing the total breadth of my expertise to this place as a way to additional broaden the visibility of the Lap-Band® Program and ReShape’s complete suite of weight reduction options to each customers and bariatric surgeons, worldwide,” added Mr. Ansari.

Previous to becoming a member of Reshape, since November 2020, Mr. Ansari was the Chief Industrial Officer and Normal Supervisor of Biedermann-Motech Inc., a mid-sized, worldwide, household owned and operated group of firms centered on the event, manufacturing and distribution of modern implants and devices for spinal and extremity surgical procedure. From August 2019 till November 2020, he was Govt Vice President – Gross sales & Advertising and marketing at Biocell Backbone Consulting, Inc. the place he was chargeable for commercializing the corporate’s modern neuromodulation machine for peripheral ache. Earlier than that, from January 2015 till July 2019, he was Senior Vice President World Gross sales at Enteromedics, throughout which era he led a 700% improve in machine gross sales and was a key member of the manager due diligence staff chargeable for buying the Lap-Band® enterprise. Earlier than that, from January 2013 to January 2015, he was President/Unique Biomet-Lanx Distributor at Biocell Backbone, LLC, and for 3 years previous to that, served in positions of accelerating accountability at Lanx, Inc., a backbone orthopedic medical machine producer, subsequently acquired by Zimmer Biomet. Earlier in his profession, Mr. Ansari honed his gross sales and distributorship expertise at firms together with Globus Medical, Inc., Biomet Orthopaedics Inc. (now Zimmer Biomet), Medtronic Sofamor-Danek, Johnson & Johnson DePuy Ortho Tech (now DePuy Synthes) and Stryker Company. Mr. Ansari holds a Bachelor of Arts diploma from Winthrop College.

About ReShape Lifesciences™
ReShape Lifesciences™ is the premier international weight reduction and metabolic health-solutions firm, providing an built-in portfolio of physician-led, confirmed services and products that handle and deal with weight problems and metabolic illness. The FDA-approved Lap-Band® Program gives minimally invasive, long-term therapy of weight problems and is an alternative choice to extra invasive surgical stapling procedures such because the gastric bypass or sleeve gastrectomy. The ReShape Vest™ System is an investigational (exterior the U.S.) minimally invasive, laparoscopically implanted medical machine that wraps across the abdomen, emulating the gastric quantity discount impact of standard weight-loss surgical procedure. It helps allow fast weight reduction in overweight and morbidly overweight sufferers with out completely altering affected person anatomy. reshapecare™ is a digital weight-management program that helps life-style modifications for all weight-loss sufferers led by board licensed well being coaches to assist them preserve the load off over time. The just lately launched ReShape Market™ is an internet assortment of high quality wellness merchandise curated for all customers to assist them obtain their well being targets. For extra info, please go to www.reshapelifesciences.com

Ahead-Wanting Protected Harbor Assertion
This press launch might comprise forward-looking statements inside the which means of the Non-public Securities Litigation Reform Act of 1995. Precise outcomes might differ materially from these mentioned attributable to recognized and unknown dangers, uncertainties, and different elements. These forward-looking statements usually might be recognized by means of phrases comparable to “anticipate,” “plan,” “anticipate,” “might,” “might,” “intend,” “will,” “proceed,” “future,” different phrases of comparable which means and using future dates. Ahead-looking statements on this press launch embody statements about our expectation that the advertising and marketing marketing campaign ought to proceed to advertise elevated demand for Lap-Band® procedures and, thus, probably a major improve in revenues for ReShape. These and extra dangers and uncertainties are described extra absolutely within the firm’s filings with the Securities and Trade Fee, together with these elements recognized as “threat elements” in our most up-to-date Annual Report on Type 10-Okay and subsequent Quarterly Stories on Type 10-Q. We’re offering this info as of the date of this press launch and don’t undertake any obligation to replace any forward-looking statements contained on this doc on account of new info, future occasions or in any other case, besides as required by regulation.

CONTACTS
ReShape Lifesciences Investor Contact:
Thomas Stankovich
Chief Monetary Officer
949-276-6042
ir@ReShapeLifesci.com

Investor Relations Contact:
Rx Communications Group
Michael Miller
(917)-633-6086
mmiller@rxir.com

Advertisement

LEAVE A REPLY

Please enter your comment!
Please enter your name here